PALI insider filing amends grant to 182,000 RSUs at $0

Rhea-AI Filing Summary

Palisade Bio, Inc. (PALI) filed an amended Form 4 reporting a corrected equity award to a director. On 10/06/2025, the reporting person acquired 182,000 Restricted Stock Units (RSUs) at $0, with 182,000 derivative securities beneficially owned directly after the transaction.

The amendment corrects a previously reported grant of 1,538,700 RSUs; the issuer has rescinded 1,356,700 of that prior amount. Each RSU represents a right to receive one share of common stock; until sufficient shares are reserved under the 2021 Equity Incentive Plan, RSUs may be settled in cash upon vesting.

The RSUs vest in three equal annual installments, with the first installment vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, subject to continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Williams Donald Allen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	182,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 182,000 shares (Direct)

Footnotes (1)

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. This amended Form 4 is being filed to correct the previously reported grant amount of 1,538,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 1,356,700 RSUs of the previously reported grant of 1,538,700 RSUs. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Williams Donald Allen

(Last) (First) (Middle)

1902 WRIGHT PLACE, SUITE 200

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
10/08/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/06/2025		A		182,000(2)		(3)	(3)	Common Stock	182,000	$0	182,000	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash.

2. This amended Form 4 is being filed to correct the previously reported grant amount of 1,538,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 1,356,700 RSUs of the previously reported grant of 1,538,700 RSUs.

3. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.

	/s/ Ryker Willie, Attorney-in-Fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Palisade Bio (PALI) report in this Form 4/A amendment?

An amended director equity award showing acquisition of 182,000 RSUs on 10/06/2025 at $0, owned directly.

How was the previously reported RSU grant corrected for PALI?

A prior total of 1,538,700 RSUs was corrected; the issuer rescinded 1,356,700 RSUs, leaving 182,000.

What is the vesting schedule for the 182,000 RSUs at PALI?

They vest in three equal annual installments, first on the earlier of the 2026 annual meeting or the anniversary of October 6, 2025.

Can the PALI RSUs be settled in cash?

Yes. Until sufficient shares are reserved under the 2021 Equity Incentive Plan, vested RSUs may be settled in cash.

What is the ownership form after the transaction for PALI's director?

The 182,000 derivative securities are reported as Direct (D) ownership.

What does each PALI RSU represent?

Each RSU represents a contingent right to receive one share of Palisade Bio common stock, subject to plan conditions.